Saccharomyces boulardii Tht 500101 changes gut microbiota and ameliorates hyperglycaemia, dyslipidaemia, and liver inflammation in streptozotocin-diabetic mice.

摘要: Type 1 diabetes mellitus (T1DM) is a disorder resulting from chronic autoimmune destruction of insulin-producing pancreatic β-cells, lack insulin production and hyperglycaemia. The aim this study was to evaluate the hypothesis that streptozotocin-diabetic mice treated with Saccharomyces boulardii THT 500101 strain present improvement glucose triglycerides metabolism, reduction liver inflammation concomitant beneficial impact in gut microbiota profile. C57BL/6 male were randomly assigned into three groups: Control, Diabetes, Diabetes+Probiotic, euthanised 8 weeks after probiotic administration. Mice submitted treatment presented reduced glycemia comparison diabetic group, which correlated an increase C-peptide level hepatic glycogen content. Fat metabolism significantly altered streptozotocin-induced S. regulated it, leading decrease serum secretion, storage modulation inflammatory phenotypic changes seen found be broadly associated microbioma animals, increased proportion Bacteroidetes, Firmicutes Deferribacteres, decreased Proteobacteria Verrucomicrobia phylum. Thus, data here show up novel potential therapeutic role for attenuation diabetes-induced complications.